Analystreport

Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.

Collegium Pharmaceutical, Inc.  (COLL) 
Last collegium pharmaceutical, inc. earnings: 2/27 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.collegiumpharma.com